Targeting CD117 with Astatine-211 to treat Acute Myeloid Leukemia and Myelodysplastic Syndrome
Official title: CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Funded at Fred Hutchinson Cancer Center · NIH-10670383 · Data updated 2026-11-12
This study is testing a new treatment that uses a special combination of antibodies and a radioactive substance to help patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) by targeting cancer cells more directly while protecting healthy ones.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $236,878 |
| NIH project number | 5R21CA245598-02 |
| Project ID | NIH-10670383 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or myelodysplastic syndrome who have not responded well to standard treatments.
✕Less likely to help
Patients with other types of blood cancers or those who are not eligible for targeted therapies may not benefit from this research.
What this research studies
This research investigates the use of a targeted therapy that combines monoclonal antibodies with a radioactive substance called astatine-211 to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The approach focuses on delivering high doses of radiation directly to cancer cells while minimizing damage to surrounding healthy cells. By targeting the CD117 receptor, which is important for the growth and survival of blood cells, this therapy aims to improve treatment outcomes for patients. The study will explore the effectiveness and safety of this method in a clinical setting.
Why it matters
Potential benefit: If successful, this research could provide a more effective and targeted treatment option for patients suffering from AML and MDS.
How similar studies have gone: Previous research has shown promise in using targeted radioimmunotherapy for blood cancers, but this specific approach using astatine-211 is relatively novel.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Walter, Roland Bruno — Fred Hutchinson Cancer Center
- Study coordinator: Walter, Roland Bruno
Related research
Other NIH-funded projects on the same topics.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
New treatment options for myelodysplastic syndrome and acute myeloid leukemia
This study is exploring new treatment options for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by looking at their genetic makeup and developing targeted therapies that could help improve their health.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.